Thus, to determine if FASN expression is essential for cell growth and survival of high-grade serous carcinoma cells (including those that are resistant to paclitaxel or carboplatin), we applied C93, a second generation FASN inhibitor, to ovarian cancer cell lines (including SKOV3, A2780, and OVCAR3). Here, FASN is linked to serous adenocarcinoma.